Neoplasms

All Conditions

Mouth and Tooth Diseases

Rare Diseases

Adenoma

Salivary Gland Neoplasms

Adenoma, Pleomorphic

Syringoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Mouth Neoplasms

Head and Neck Neoplasms

Mouth Diseases

Stomatognathic Diseases

Salivary Gland Diseases

Neoplasms, Adnexal and Skin Appendage

Oral Cancer

Antineoplastic Agents

All Drugs and Chemicals

Panitumumab

Antineoplastic Agents, Immunological

Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-8 doses).

Radiation 64-70Gy (2.0 Gy/day, 5 days/week)

Radiation

2.5 mg/Kg IV, weekly during RT. 6-7 weeks

Michael K. Gibson, MD

Standard therapy for high-risk or locally advanced salivary gland malignancies is surgery followed by postoperative radiation therapy. Retrospective studies have shown the superiority of combined modality therapy compared to surgery alone for patients with advanced T or N stage. Despite the addition of postoperative radiation therapy, the five-year survival for locally advanced salivary gland malignancies is poor (less than 60%). In salivary gland malignancies, the epidermal growth factor receptor (EGFR) is expressed in 25-85%; in certain histological types, like salivary duct carcinomas, the expression is higher. EGFR is a promising target of anticancer therapy. In squamous cell carcinoma of the head and neck, a phase III trial utilizing cetuximab added to radiation therapy improved both locoregional control and overall survival compared to radiation alone. Panitumumab is a novel, human, IgG2 EGFR monoclonal antibody that may be better tolerated and more efficacious than cetuximab. Here, the investigators suggest that the addition of panitumumab to standard radiotherapy in locally-advanced salivary gland malignancies will improve recurrence-free survival (RFS).

Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies

Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies

Amgen

University of Pittsburgh

Spots Global Cancer Trial Database for mixed salivary gland tumor